At the news
? NEUTRALIMPACT 4/10 8-K filed Jun 17, 2026 at 16:05 ET
Rigel Pharmaceuticals completed its previously announced exclusive global license agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), an FDA-approved ER+/HER2- breast cancer treatment. The deal closed following HSR clearance, with Rigel paying the $70 million upfront cash consideration. This milestone de-risks the transaction but provides no new financial terms beyond the original announcement.
- License agreement with Arvinas/Pfizer for VEPPANU (vepdegestrant) became effective on June 11, 2026.
- Company paid a one-time upfront payment of $70.0 million to the licensors upon closing.
- HSR waiting period terminated early and all other closing conditions satisfied.
- Rigel granted exclusive global rights to develop, manufacture and commercialize VEPPANU.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access